USA flag logo/image

An Official Website of the United States Government

ANTIMICROBIAL COATING FOR BIOFILM INHIBITION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
60532
Program Year/Program:
2002 / STTR
Agency Tracking Number:
AI051816
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
BIOMEDICAL DEVELOPMENT CORPORATION
A152 ASTeCC Building Lexington, KY 40506-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: ANTIMICROBIAL COATING FOR BIOFILM INHIBITION
Agency: HHS
Contract: 1R41AI051816-01
Award Amount: $100,000.00
 

Abstract:

Description(provided by applicant): Candida is the third leading cause of catheter-related nosocomial bloodstream infections. Indwelling devices have been shown to support colonization and biofilm formulation by Candida. Intravenous lines are the most frequent indwelling device and are the single most common cause of candidemia. Once a Candida biofilm forms in vivo, removal of the substrate that is supporting the biofilm growth is almost always required to eliminate the infection. Unfortunately, in many instances removal is impossible due to deteriorated patient condition, anatomical location, or underlying disease. The goal of this project is to incorporate an antifungal agent into unique, patented formulations to create a coating for medical devices that is resistant to C. albicans. A coating and antifungal delivery system that could extend the time and/or increase the rate of delivery and achieve a higher concentration of antifungal agents to a C. albicans-susceptible site would have enormous therapeutic advantages over systemic and inefficacious topical routes of delivery. To demonstrate the feasibility of this approach, the specific aims are to optimize the coating formulation for use as short-term antifungal coatings for medical devices, evaluate the coatings for antifungal activity in vitro, and to perform an intramuscular implantation study in rabbits. PROPOSED COMMERCIAL APPLICATION: Candida albicans is by far the most frequently isolated human mycotic agent. The large number of immunosuppressed patients with indwelling devices combined with the extensive social and economic costs associated with treating C. albicans-related infections serve as justification for the pursuit of alternative therapies.

Principal Investigator:

H. R. Rawls
2103080636
BDC@BIODEVCORP.COM

Business Contact:

Siegel Gregg
2103080636
GSIEGEL@BIODEVCORP.COM
Small Business Information at Submission:

BIOMEDICAL DEVELOPMENT CORPORATION
BIOMEDICAL DEVELOPMENT CORP 500 SANDAU, STE 200 SAN ANTONIO, TX 78216

EIN/Tax ID: 742330067
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Research Institution Information:
UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER
UT
SAN ANTONIO, TX 78249
RI Type: Nonprofit college or university